Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Profiling · 1 trial · 1 indication
To characterise the inhalation profiles of healthy volunteers, volunteers with mild, moderate and severe asthma and volunteers with mild, moderate and severe COPD, through the novel DPI, using the IPR
To characterise the inhalation profiles of healthy volunteers, volunteers with mild, moderate and severe asthma and volunteers with mild, moderate and severe COPD, using pharangometry
| Arm | Type | Description |
|---|---|---|
| Inhalation Profiling | OTHER | All subjects have Inhaltion profiling, there are no other arms. |
| Name | Type | Description |
|---|---|---|
| Inhalation Profiling | PROCEDURE | All subects recieve Inhaltion Profiling there are no interventions. |
Inclusion Criteria: A subject will be eligible for inclusion in this study only if all of the following criteria apply. * All volunteers must be aged between 21 to 70 years inclusive and be competent to understand and give informed consent. * All female volunteers of child bearing potential must h...
Profiling is an investigational drug being studied for use in chronic obstructive pulmonary disease (COPD). It is currently in Phase 1 clinical development. The drug is being developed by GSK plc (GSK) as a potential treatment for respiratory conditions.
Profiling is being developed by GSK plc, a global biopharmaceutical company traded on the stock exchange under the ticker symbol GSK. The company is conducting clinical research to evaluate the drug's potential in treating chronic obstructive pulmonary disease.
Profiling is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The drug is being studied for its potential use in treating chronic obstructive pulmonary disease.
Profiling has one completed clinical trial registered under NCT01345266. This Phase 1 study, titled 'Characterisation of Healthy Volunteers, Asthma and Chronic Obstructive Pulmonary Disease Patients for Inhalation Profile, Pharyngometry, Spirometric Indices and Lung Morphometry,' enrolled 106 participants in Belgium.
Profiling is the name used for this investigational drug in clinical development. No alternative names have been reported for this asset. It is being studied specifically for its potential application in chronic obstructive pulmonary disease.